# Diagnostic accuracy of an enzyme-based point-of-care test versus Nugent score for bacterial vaginosis among pregnant women attending routine antenatal care in Zambia

**Authors:** Sumire Sorano, Enesia Banda Chaponda, Massimo Mirandola, Ephraim Chikwanda, Vivian Mwewa, Joyce M. Mulenga, Mike Chaponda, Ludovica Ghilardi, Emma M. Harding-Esch, Chris Smith, Mitsuaki Matsui, Daniel Chandramohan, Mohamed Mahmoud Ali, Karel Blondeel, Magnus Unemo, Igor Toskin, R. Matthew Chico

PMC · DOI: 10.1186/s12879-026-12714-y · BMC Infectious Diseases · 2026-01-31

## TL;DR

A study in Zambia found that a point-of-care test for bacterial vaginosis among pregnant women had high specificity but low sensitivity compared to a standard diagnostic method.

## Contribution

This study evaluates the diagnostic accuracy and operational feasibility of a point-of-care test for bacterial vaginosis in a resource-limited setting.

## Key findings

- The OSOM® BVBlue® test had a sensitivity of 41.3% and specificity of 93.1% compared to the Nugent score.
- Most pregnant women were willing to wait up to 20 minutes for test results.
- Cold-chain requirements and short shelf life were identified as significant implementation challenges.

## Abstract

Bacterial vaginosis (BV) is associated with adverse pregnancy outcomes. OSOM® BVBlue® is a chromogenic point-of-care (POC) test that detects sialidase, an enzyme produced by Gardnerella vaginalis and some other anaerobic bacteria associated with BV. This study, part of the World Health Organization’s global ProSPeRo study, aimed to evaluate the performance of this POC test compared with the Nugent score reference standard among pregnant women in Zambia. Additionally, the operational characteristics and patient acceptability of the POC test were evaluated.

Pregnant women attending four health centres in Nchelenge, Zambia, for antenatal care between 15 February and 26 May 2023 participated. Clinician-collected vaginal swabs for OSOM® BVBlue® and Nugent scoring were obtained from each participant. POC test results were read independently by two staff members. Study staff completed a questionnaire on the operational characteristics of the POC test, whereas participants were asked about the length of time that they would be willing to wait for POC test results.

Paired POC and reference test vaginal swabs from 999 participants were analysed. Overall, 23.1% (231/999) tested positive for BV by Nugent score. Overall sensitivity and specificity of OSOM® BVBlue® were 41.3% (95% confidence interval [CI] 25.4–59.2%) and 93.1% (95% CI 89.8–95.4%), respectively. Inter-rater agreement was 99.6% (Cohen’s Kappa 0.984). Most pregnant women, 97.9% (978/999), were willing to wait up to 20 min for a POC test result, and 59.2% (591/999) up to 30 min. Of 14 study staff members, all found the POC test easy to use and instructions clear, 13 felt the results were easy to interpret, with 12 reporting test results were available within 25 min. Cold-chain requirements and short shelf life were perceived as significant challenges.

Overall, OSOM® BVBlue® yielded sub-optimal sensitivity. The findings from this study are valuable for the development of minimal and optimal product profiles for POC tests for BV. These profiles, in turn, may guide future research and development for this prevalent condition with important sexual and reproductive health consequences. Logistical challenges need to be addressed for effective implementation of POC testing in resource-limited settings.

PACTR202302766902029.

The online version contains supplementary material available at 10.1186/s12879-026-12714-y.

## Linked entities

- **Diseases:** bacterial vaginosis (MONDO:0005316)

## Full-text entities

- **Diseases:** trichomoniasis (MESH:D014245), ulcers (MESH:D014456), Infectious Diseases (MESH:D003141), warts (MESH:D014860), HIV (MESH:D015658), abortion (MESH:D000026), BV (MESH:D016585), Syphilis (MESH:D013587), infection (MESH:D007239), rashes (MESH:D005076), itching (MESH:D011537), endometritis (MESH:D004716), pain (MESH:D010146), allergy (MESH:D004342), abdominal pain (MESH:D015746), dysbiosis (MESH:D064806), STI (MESH:D012749), preterm birth (MESH:D047928)
- **Chemicals:** clindamycin (MESH:D002981), sialic acid (MESH:D019158), Metronidazole (MESH:D008795)
- **Species:** Prevotella (genus) [taxon 838], Mobiluncus (genus) [taxon 2050], Enterobacteria phage SfV (species) [taxon 55884], Human immunodeficiency virus 1 (no rank) [taxon 11676], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Lactobacillus (genus) [taxon 1578], Homo sapiens (human, species) [taxon 9606], Bacteroides (genus) [taxon 816], Gardnerella vaginalis (species) [taxon 2702]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12862899/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12862899/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12862899/full.md

---
Source: https://tomesphere.com/paper/PMC12862899